Galactosyl transferase mutant and application of galactosyl transferase mutant in preparation of flavonoid compounds
By performing point mutation on galactosyltransferase VcUFGT, UDP-galactosyltransferase mutants are generated, the problem of high cost of extraction of hypericin is solved, the efficient biosynthesis of flavonoids is achieved, and the catalytic efficiency is improved. Reduced production costs.
Patent Information
- Application Number
- CN202411216107.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-30
AI Technical Summary
Hypericin extracting costs are high, limiting its application scope.
By performing point mutation on galactosyltransferase VcUFGT, UDP-galactosyltransferase mutants are generated, and the enzyme is used to catalyze the synthesis of flavonoids, which improves the catalytic efficiency and is suitable for industrial production.
The mutant's activity is increased by more than 1.5 times, providing a foundation for efficient biosynthesis of the flavonoid compound hypericin and reducing production costs.
Smart Images

Figure CN118909996A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of enzymology, and specifically relates to a galactosyltransferase mutant and application thereof in the preparation of flavonoid compounds. Background Art
[0002] Hyperoside is also known as hyperoside-3-O-β-D-pyranogalactoside. The aglycone is hyperoside and the glycosyl is pyranogalactose. The 3-position O atom of hyperoside is connected to the glycosyl by a β-glycosidic bond. The molecular formula is C 21 H 20 O 12 , molecular weight 464.3763. Hyperoside is a flavonoid compound extracted from Hypericum perforatum fruit. It has the effects of anti-oxidation, lowering blood pressure, lowering blood lipids, dilating coronary arteries, and treating chronic bronchitis. It is often used in the field of medicine and health products.
[0003] However, at present, hyperoside is mostly obtained by extraction, such as using Hypericum perforatum as raw material, and extracting by water distillation, solvent extraction, supercritical fluid extraction, direct steam distillation, microwave-assisted extraction process or supercritical CO2 method. There is inevitably a problem of high extraction cost, which makes hyperoside expensive and limits its application range to a certain extent. Summary of the invention
[0004] The invention provides a UDP-galactosyltransferase mutant and application thereof in preparing flavonoid compounds. The UDP-galactosyltransferase mutant can catalyze the synthesis of flavonoid compounds with high efficiency and is suitable for industrial production of flavonoid compounds.
[0005] The present invention provides a UDP-galactosyltransferase mutant, comprising point mutation of galactosyltransferase VcUFGT, wherein the point mutation comprises point mutation of an amino acid in the amino acid sequence of galactosyltransferase VcUFGT to alanine.
[0006] Preferably, the amino acid sequence of the galactosyltransferase VcUFGT is shown in SEQ ID No.2.
[0007] Preferably, the point mutation includes any of the following point mutations in the amino acid sequence shown in SEQ ID No. 2: H82A, V139A, G141A, P186A, N245A, V282A or S307A.
[0008] The present invention also provides a gene encoding the UDP-galactosyltransferase mutant.
[0009] Preferably, the coding gene is mutated based on the coding gene of galactosyltransferase VcUFGT;
[0010] The nucleotide sequence of the gene encoding the galactosyltransferase VcUFGT is shown in SEQ ID No.1.
[0011] Preferably, the nucleotide sequence of the encoding gene of the UDP-galactosyltransferase mutant undergoes any of the following mutations compared to SEQ ID No. 1: positions 244 to 246 mutate from CAC to GCG, positions 416 to 417 mutate from TC to CG, positions 422 to 423 mutate from GA to CG, positions 556 to 558 mutate from CCA to GCG, positions 733 to 735 mutate from AAC to GCG, positions 845 to 866 mutate from TC to CG, and positions 919 to 921 mutate from TCT to GCG.
[0012] The present invention also provides a recombinant expression vector comprising the above encoding gene.
[0013] The present invention also provides a recombinant host comprising the above coding gene and expressing the above UDP-galactosyltransferase mutant.
[0014] The present invention also provides the use of the UDP-galactosyltransferase mutant or the product prepared by using the recombinant host in catalyzing the synthesis of flavonoid compounds.
[0015] The present invention also provides a method for producing flavonoid compounds by in vitro catalysis, comprising taking quercetin and UDP-galactoside as substrates, using the above-mentioned UDP-galactosyltransferase mutant or the product prepared by the above-mentioned recombinant host as a catalytic enzyme, and catalytically synthesizing the flavonoid compounds.
[0016] Beneficial effects: The present invention provides a UDP-galactosyltransferase mutant, which is obtained by site-directed mutation of one of the amino acids in the amino acid sequence of the wild-type galactosyltransferase VcUFGT to alanine (A). The effects of a series of mutants H82A, V139A, G141A, P186A, N245A, V282A and S307A are verified in the examples. The mutants can all be used as substrates for enzyme-catalyzed reactions to generate flavonoid compounds (hyperoside), and the specific enzyme activity of the mutants is increased by more than 1.5 times that of the wild-type, which is a flavonoid compound (hyperoside, Figure 1 ) provides an effective application basis for the biosynthesis of BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is the structural formula of hyperoside;
[0018] Figure 2 This is a schematic diagram of the reaction of quercetin synthesizing hyperoside catalyzed by galactosyltransferase;
[0019] Figure 3 is the plasmid map of the recombinant plasmid pET-30a(+)-VcUFGT;
[0020] Figure 4 It is the SDS-PAGE electrophoresis diagram of the wild type and mutant of galactosyltransferase VcUFGT;
[0021] Figure 5 This is a liquid phase comparison of the reaction products of quercetin synthesizing hyperoside catalyzed by galactosyltransferase and its mutant (detection wavelength: 280nm);
[0022] Figure 6 The results are a comparison of the enzyme activities of galactosyltransferase and its mutants in catalyzing the synthesis of hyperoside from quercetin. DETAILED DESCRIPTION
[0023] The present invention provides a UDP-galactosyltransferase mutant, comprising point mutation of galactosyltransferase VcUFGT, wherein the point mutation comprises point mutation of an amino acid in the amino acid sequence of galactosyltransferase VcUFGT to alanine.
[0024] The mutant of the present invention is based on galactosyltransferase VcUFGT, and site-directed mutation is performed on the galactosyltransferase VcUFGT, thereby obtaining a large number of mutants. The amino acid sequence of the galactosyltransferase VcUFGT of the present invention is preferably as shown in SEQ ID No.2: Met SerAsnPhe Ser Lys AspArg His ValAlaVal LeuPro Phe Pro Phe Ser Thr His AlaAla Pro Ile Leu Ser IleIleArgArg PheAla SerAlaSer ProAsp Val Thr Phe Ser Phe Phe Ser Ile Pro Gln SerIle Gln Thr Leu Phe ProSer GluAsn ProAsp SerAsn Ile Lys Pro TyrValVal SerAspGly Val Pro Glu Gly TyrVal Phe Ser Gly Lys His His GluAsp Ile Asn Leu Phe LeuAlaAla Gly Lys Glu SerLeu Lys Ala Gly Met Lys AlaAla GluAla Glu Ile Gly ArgArg Ile Asp Cys ValValAlaAsp Ala Phe Leu Trp Phe Thr Gln Glu LeuAla Glu GluMet Gly Val Pro TrpIle Thr Leu Trp Val Ser Gly Ala Cys Ser Leu Ser Ala His CysTyr ThrAsp Leu IleArg Glu Thr Val Gly Met His Asp Ile Ala GlyArg GluAsn GluIle Val Lys Phe ValPro Gly Phe Ser Glu Val Arg Leu Gly Asp Leu Pro Ser Gly ValVal Tyr GlyAsn LeuGlu SerPro Phe Ser Met Met Leu TyrAsn Met Gly GlnVal LeuHis Lys Ala Thr AlaVal Ala Ile Asn Ser Phe Glu Glu Leu Glu Pro Glu His Asn LysVal Leu Glu SerLys Phe Lys Lys LeuLeuAsn Cys Gly Pro Phe Asn Ser Ile Ser ProPro Pro Pro ProSer SerAsn Leu Asp Lys Tyr Gly Cys Ile Pro Trp Leu Asp Gln HisLys ThrArg SerValAla Tyr Ile Gly Phe Gly Ser ValAla Thr Pro Pro Pro Val Glu IleAlaAlaLeuAla GluAla Leu GluAla Ser Gly Thr Pro Phe Leu Trp Ser LeuArgAspAsn Phe LysLys His Leu Pro Glu Gly Phe Leu Lys Arg Thr Ser Glu Leu Gly Lys IleValAla TrpAla Pro Gln Val Gln Val LeuAla His Ser Ser Ile Gly Val Phe Ile Asn HisCys GlyTrp Asn SerVal Leu Glu Ser Ile ValAla GlyVal Pro Ile Ile GlyArg Pro PhePheGly Asp His Gln Val Asp Thr Trp Met Val Glu Asn Val Trp Lys Ile Gly ValArgVal Glu Gly Gly Val Phe Thr Lys Ser Gly Thr Met SerAla Leu Glu Leu Val LeuSerGln Glu Lys Gly Lys Glu LeuArg Glu Gln Thr Gly Lys Tyr Lys Glu PheAla LeuLysAla Val Gly Pro Lys GlyArg Ser Thr GlnAsn LeuAsn Thr Leu Leu GluLeuValArgGly TyrAsn Ile*。
[0025] The point mutation of the present invention preferably includes any of the following point mutations occurring in the amino acid sequence shown in SEQ ID No. 2: H82A, V139A, G141A, P186A, N245A, V282A or S307A, and each mutant is named according to the point mutation site and the amino acid sequence before and after the mutation, such as mutant H82A obtained by H82A point mutation, mutant V139A obtained by V139A point mutation, mutant G141A obtained by G141A point mutation, mutant P186A obtained by P186A point mutation, mutant N245A obtained by N245A point mutation, mutant V282A obtained by V282A point mutation, and mutant S307A obtained by S307A point mutation.
[0026] The present invention also provides a gene encoding the UDP-galactosyltransferase mutant.
[0027]
[0028] The nucleotide sequence of the encoding gene of the mutant of the present invention has the same nucleotides at the positions corresponding to the point mutation, such as the nucleotide sequence of the encoding gene of the mutant H82A is a mutation from CAC to GCG at positions 244 to 246 of the sequence shown in SEQ ID No.1; the nucleotide sequence of the encoding gene of the mutant V139A is a mutation from TC to CG at positions 416 to 417 of the sequence shown in SEQ ID No.1; the nucleotide sequence of the encoding gene of the mutant G141A is a mutation from GA to CG at positions 422 to 423 of the sequence shown in SEQ ID No.1; the nucleotide sequence of the encoding gene of the mutant P186A is a mutation from CCA to GCG at positions 556 to 558 of the sequence shown in SEQ ID No.1; the nucleotide sequence of the encoding gene of the mutant N245A is a mutation from AAC to GCG at positions 733 to 735 of the sequence shown in SEQ ID No.1; the nucleotide sequence of the encoding gene of the mutant V282A is a mutation from AAC to GCG at positions 733 to 735 of the sequence shown in SEQ ID The 845th to 866th positions of the sequence shown in No.1 were mutated from TC to CG; the nucleotide sequence of the coding gene of the mutant S307A was mutated from TCT to GCG at the 919th to 921th positions of the sequence shown in SEQ ID No.1.
[0029] The present invention also provides a recombinant expression vector comprising the above encoding gene.
[0030] The present invention does not specifically limit the gene source of the galactosyltransferase VcUFGT, which can be isolated from the Emerald variety (Vaccinium corymbosum L.) of southern highbush blueberry, isolated from recombinant engineering bacteria containing the above encoding gene, or artificially synthesized. The recombinant expression vector of the present invention preferably uses a prokaryotic expression vector as the basic vector skeleton, such as a pET series vector.
[0031] When constructing the recombinant expression vectors of the mutants, the present invention preferably uses the galactosyltransferase VcUFGT as a template and uses the primer pairs shown in Table 1 to perform site-directed mutagenesis to obtain the mutants.
[0032] Table 1 Primer sequences for mutant construction
[0033]
[0034]
[0035] The present invention also provides a recombinant host comprising the above coding gene and expressing the above UDP-galactosyltransferase mutant.
[0036] The recombinant host of the present invention preferably includes recombinant bacteria, recombinant fungi or recombinant plants. In the embodiments, recombinant bacteria are used as an example for illustration, but they cannot be regarded as the entire protection scope of the present invention.
[0037] In the embodiment of the present invention, the above-mentioned recombinant expression vector is transformed into Escherichia coli competent cells by genetic transformation method to obtain recombinant bacteria; then the recombinant bacteria are subjected to IPTG-induced prokaryotic expression, and the recombinant protein is extracted and purified from the supernatant of bacterial cell crushing to obtain various mutant proteins.
[0038] The genetically engineered bacteria of each mutant in the embodiment of the present invention are recombinant Escherichia coli containing a recombinant vector of a mutant encoding gene; the recombinant plasmid is chemically transformed into BL21 (DE3) competent cells, and after recovery for 1 hour, it is spread on an LB plate containing 50 μg / mL kanamycin resistance, cultured overnight at 37°C, and sequenced to obtain recombinant Escherichia coli genetically engineered bacteria. The induction expression conditions of the genetically engineered bacteria preferably include: inoculating Escherichia coli into an LB medium containing 50 μg / mL kanamycin resistance, and shaking and culturing at 37°C and 200 rpm until the OD 600 When the concentration was about 0.6, IPTG was added at a final concentration of 0.1 mM, and the culture was carried out at 16°C and 180 rpm for 20 h. The bacteria were collected by centrifugation.
[0039] The present invention also provides the use of the UDP-galactosyltransferase mutant or the product prepared by using the recombinant host in catalyzing the synthesis of flavonoid compounds.
[0040] The mutant of the present invention has the ability to catalyze the synthesis of flavonoid compounds from quercetin, and can catalyze Figure 2 The reactions shown hereby generate flavonoids including hyperoside.
[0041] The present invention also provides a method for producing flavonoid compounds by in vitro catalysis, comprising taking quercetin and UDP-galactoside as substrates, using the above-mentioned UDP-galactosyltransferase mutant or the product prepared by the above-mentioned recombinant host as a catalytic enzyme, and catalytically synthesizing the flavonoid compounds.
[0042] The temperature of the catalytic reaction for catalyzing the synthesis of flavonoid compounds such as hyperoside of the present invention is preferably 20-40° C., and the pH value is preferably 7.0-9.0.
[0043] The enzymatic reaction system of the present invention preferably includes, based on 200 μL, 0.01-0.1 M Tris-HCl buffer (pH=7.0-9.0), 1-5 mM glycosyl donor (UDP-galactose), 0.5-2.5 mM glycosyl acceptor substrate (quercetin) and 50-100 μg purified enzyme.
[0044] In order to further illustrate the present invention, a galactosyltransferase mutant provided by the present invention and its application in the preparation of flavonoids are described in detail below in conjunction with examples, but they should not be construed as limiting the scope of protection of the present invention.
[0045] Example 1 Construction of recombinant plasmid and expression strain of galactosyltransferase VcUFGT
[0046] Yisheng Biotechnology Co., Ltd. The Plant RNAKit plant RNA extraction kit was used to extract RNA from ripe blueberry fruits (Vaccinium corymbosum L.) that had been quick-frozen in liquid nitrogen. TM RT reagent Kit was used to reverse transcribe the extracted RNA into blueberry fruit cDNA and stored at -80℃ for future use.
[0047] Primers VcUFGT-BamHI-F and VcUFGT-XhoI-R were designed, and PrimeStar DNA polymerase was used to amplify the VcUFGT gene from blueberry fruit cDNA based on PCR technology. The PCR system was as follows: 32.5μL ddH2O, 10μL 5×buffer, 4μL 2.5mM dNTPs, 1μL 10mM primer VcUFGT-BamHI-F, 1μL 10mM primer VcUFGT-XhoI-R, 1μL blueberry genomic cDNA, 0.5μL PrimeStar DNA polymerase. The PCR program was as follows: 98℃ pre-denaturation for 2min, followed by 35 cycles (98℃ denaturation for 10s, 55℃ annealing for 15s, 72℃ extension for 1.5min), 72℃ continued extension for 5min, and then stored at 4℃. The PCR product was purified using a PCR product purification kit from Beijing Quanshijin Biotechnology Co., Ltd. and ligated to the vector pET-30a(+) that had been digested with BamHI and XhoI restriction endonucleases. Figure 3 After the ligation product shown was transformed into Escherichia coli BL21 (DE3), it was spread on a plate containing kanamycin resistance and inverted in a constant temperature incubator at 37°C for overnight culture (12-16h). A single colony was picked and added to a test tube containing 5mL LB liquid culture medium containing kanamycin resistance, placed in a shaker and cultured overnight at 37°C and 200rpm. The bacterial solution was sent for sequencing using universal sequencing primers SeqN1 and SeqN2. According to the sequence results, the strain with correct sequencing was selected as the expression strain of the recombinant plasmid pET-30a(+)-VcUFGT.
[0048] The amplification primers and sequencing primers used in this example are as follows:
[0049] VcUFGT-BamHIF (SEQ ID No. 17): CGGATCCATGCACCATCATCATCATCA;
[0050] VcUFGT-XhoIR (SEQ ID No. 18): CCTCGAGTTAGATATTGTAACCTCTGA;
[0051] SeqN1 (SEQ ID No. 19): CAGCCGGATCTCAGTGGTGG;
[0052] SeqN2 (SEQ ID No. 20): TCTGGTATGAAAGAAACCGC.
[0053] Example 2 Construction of recombinant plasmid and expression strain of galactosyltransferase VcUFGT mutant
[0054] According to the gene sequence of galactosyltransferase VcUFGT (SEQ ID No. 1), the primers corresponding to the mutants H82A, V139A, G141A, P186A, N245A, V282A and S307A were designed (Table 1). The Fast Mutagenesis System kit of Quanshijin was used, and the recombinant plasmid pET-30a (+)-VcUFGT was used as a template to construct the mutants H82A, V139A, G141A, P186A, N245A, V282A and S307A of galactosyltransferase VcUFGT with the corresponding primers. The recombinant plasmids pET-30a(+)-H82A, pET-30a(+)-V139A, pET-30a(+)-G141A, pET-30a(+)-P186A, pET-30a(+)-N245A, pET-30a(+)-V282 and pET-30a(+)-VcUFGT-S307A containing 141A, P186A, N245A, V282 and S307A.
[0055] The recombinant plasmids pET-30a(+)-H82A, pET-30a(+)-V139A, pET-30a(+)-G141A, pET-30a(+)-P186A, pET-30a(+)-N245A, pET-30a(+)-V282 and pET-30a(+)-S307A of the galactosyltransferase VcUFGT mutant were transformed into Escherichia coli BL21(DE3) respectively, and then spread on a plate containing kanamycin resistance and inverted in a constant temperature incubator at 37°C for overnight culture (12-16h). A single colony was picked and added to a test tube containing 5mL LB liquid culture medium containing kanamycin resistance, placed in a shaker for overnight culture at 37°C and 200rpm, and the bacterial solution was sent for sequencing using universal sequencing primers Seq1 and Seq2. According to the sequence results, the strains with correct sequencing were selected as expression strains for recombinant plasmids pET-30a(+)-H82A, pET-30a(+)-V139A, pET-30a(+)-G141A, pET-30a(+)-P186A, pET-30a(+)-N245A, pET-30a(+)-V282 and pET-30a(+)-VcUFGT-S307A.
[0056] Example 3 Expression and purification of galactosyltransferase VcUFGT and its mutants
[0057] The expression strains of the recombinant plasmids pET-30a(+)-H82A, pET-30a(+)-V139A, pET-30a(+)-G141A, pET-30a(+)-P186A, pET-30a(+)-N245A, pET-30a(+)-V282 and pET-30a(+)-VcUFGT-S307A constructed in Example 2 were added to a test tube containing 5 mL of LB liquid culture medium containing kanamycin resistance at a ratio of 1:50, and placed in a shaker at 37°C, 200 rpm for overnight culture. Afterwards, 5 mL of the overnight cultured bacterial solution was added to 100 mL of LB liquid culture medium containing kanamycin resistance, and cultured in a shaker at 37°C, 200 rpm for 2-3 hours until the OD 600 About 0.6. Add IPTG solution with a final concentration of 0.1mM and culture in a shaker at 16℃, 180rpm for 20h to induce protein expression. Centrifuge at 8000rpm, 4℃ for 15min, collect the cells, resuspend them in 1×PBS buffer pre-frozen at 4℃, and freeze them in a -80℃ refrigerator.
[0058] The bacteria frozen in -80℃ refrigerator were placed in a 37℃ water bath to thaw, and the bacteria were ultrasonically disrupted. The ultrasonic disruption program was as follows: ultrasonic 4s, interval 2s, ultrasonic 10min. The protein was purified using the Clontech HisTALON kit of Bio-Rad Biotechnology Co., Ltd., and the relevant procedures were operated according to the instructions of the kit. Then, the protein was desalted using the PD-10 column of GE Healthcare, and the relevant operations were carried out according to the procedures recommended in the instructions. The column was placed at -80℃ for use. The amount of purified protein was about 5mg. The protein samples of the wild type and mutant of VcUFGT after purification were detected by SDS-PAGE to confirm that the bands of the purified protein samples were correct ( Figure 4 ).
[0059] Example 4 Experimental test of the enzymatic activity of galactosyltransferase VcUFGT and its mutants
[0060] The total volume of the reaction system was 200 μL, which contained 0.1 M Tris-HCl buffer (pH = 7.0), 1 mM glycosyl donor (UDP-galactose), 0.5 mM glycosyl acceptor substrate (quercetin) and about 50 μg of the purified VcUFGT protein obtained in Example 3 and its mutants.
[0061] The reaction conditions of the enzyme activity experiment were incubation in a water bath at 30°C for 16 h, followed by addition of 200 μL of methanol containing 1% formic acid to terminate the reaction, centrifugation at 12000 rpm for 3 min, and filtration of the supernatant through a 0.22 μM organic filter membrane before detection by liquid chromatography.
[0062] Instrument: ThermoFisherU3000 high performance liquid chromatograph; analytical column: Promosil C18 column (4.6×250mm, 5μm); detection wavelength: 280nm; injection 20 microliters; detection temperature: 30℃; flow rate 1mL / min, mobile phases are acetonitrile (phase A) and 1.5% formic acid solution (phase B). The elution gradient is set as follows: 0-9min, the proportion of phase A increases from 10% to 50%; 9-10min, the proportion of phase A remains at 50%; 10-15min, the proportion of phase A increases from 50% to 100%; 15-16min, the proportion of phase A decreases from 100% to 10%; 16-21min, the proportion of phase A remains at 90%. The results of the enzyme activity experiment are as follows Figure 5 and Figure 6 shown.
[0063] The specific enzyme activity of mutants H82A, V139A, G141A, P186A, N245A, V282A and S307A in catalyzing the synthesis of hyperoside from quercetin was more than 1.5 times higher than that of the wild type.
[0064] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A UDP-galactosyltransferase mutant, characterized in that The method comprises performing a point mutation on the galactosyltransferase VcUFGT, wherein the point mutation comprises mutating an amino acid point in the amino acid sequence of the galactosyltransferase VcUFGT into alanine.
2. The UDP-galactosyltransferase mutant according to claim 1, characterized in that The amino acid sequence of the galactosyltransferase VcUFGT is shown in SEQ ID No.
2.
3. The UDP-galactosyltransferase mutant according to claim 2, characterized in that The point mutation includes any of the following point mutations in the amino acid sequence shown in SEQ ID No. 2: H82A, V139A, G141A, P186A, N245A, V282A or S307A.
4. A gene encoding the UDP-galactosyltransferase mutant according to any one of claims 1 to 3.
5. The coding gene according to claim 4, characterized in that The coding gene is mutated based on the coding gene of galactosyltransferase VcUFGT; The nucleotide sequence of the gene encoding the galactosyltransferase VcUFGT is shown in SEQ ID No.
1.
6. The coding gene according to claim 5, characterized in that The nucleotide sequence of the encoding gene of the UDP-galactosyltransferase mutant undergoes any of the following mutations compared to SEQ ID No. 1: positions 244 to 246 mutate from CAC to GCG, positions 416 to 417 mutate from TC to CG, positions 422 to 423 mutate from GA to CG, positions 556 to 558 mutate from CCA to GCG, positions 733 to 735 mutate from AAC to GCG, positions 845 to 866 mutate from TC to CG, and positions 919 to 921 mutate from TCT to GCG.
7. A recombinant expression vector comprising the coding gene according to any one of claims 4 to 6.
8. A recombinant host comprising the coding gene according to any one of claims 4 to 6 and expressing the UDP-galactosyltransferase mutant according to any one of claims 1 to 3.
9. Use of the UDP-galactosyltransferase mutant according to any one of claims 1 to 3 or the product prepared by using the recombinant host according to claim 8 in catalytic synthesis of flavonoids.
10. A method for producing flavonoids by in vitro catalysis, characterized in that: The method comprises taking quercetin and UDP-galactoside as substrates, using the UDP-galactosyltransferase mutant according to any one of claims 1 to 3 or the product prepared by the recombinant host according to claim 8 as a catalytic enzyme, and catalytically synthesizing flavonoid compounds.
Citation Information
Patent Citations
Protein capable of regulating and controlling content of anthocyanin in blueberry fruit as well as encoding gene and application of protein
CN106967161A
Glycosyltransferase mutants
CN109295027A
Application of directionally mutated glycosyl transferase in synthesis of galactoside anthocyanin
CN118813574A
